股市必读：祥生医疗(688358)股东户数0.62万户，较上期减少7%

Core Viewpoint - Xiangsheng Medical (688358) reported a significant increase in net profit for Q3 2025, primarily due to improved exchange gains, despite a decline in revenue for the first three quarters of the year [1][2][3] Trading Information Summary - On October 20, 2025, the stock closed at 32.76 yuan, up 0.43%, with a turnover rate of 2.2% and a trading volume of 24,600 shares, amounting to a total transaction value of 81.94 million yuan [1] - The net outflow of main funds was 550.79 thousand yuan, accounting for 6.72% of the total transaction value, while retail investors saw a net inflow of 649.32 thousand yuan, representing 7.92% of the total [2] Shareholder and Capital Changes - As of September 30, 2025, the number of shareholders decreased to 6,167, a decline of 7.0% from June 30, 2025, with the average shareholding increasing to 18,200 shares [1][2] - The average market value of shares held per account was 598,200 yuan [1] Performance Disclosure Highlights - For the first three quarters of 2025, the company achieved a revenue of 343 million yuan, a decrease of 5.27% year-on-year, with Q3 revenue at 107 million yuan, down 6.68% [3] - The net profit attributable to shareholders for the first three quarters was 93.92 million yuan, a decline of 4.56%, while Q3 net profit was 24.22 million yuan, showing a year-on-year increase of 41.95% [3] - The non-recurring net profit for the first three quarters was 86.97 million yuan, down 2.69%, with Q3 showing a significant increase of 53.63% [3] - The weighted average return on equity was 6.63%, a decrease of 0.51 percentage points year-on-year, while Q3 saw an increase to 1.74%, up 0.49 percentage points [3] - R&D investment for the first three quarters totaled 56.57 million yuan, down 8.40%, representing 16.48% of revenue, a decrease of 0.57 percentage points [3] - The net cash flow from operating activities was 73.29 million yuan, an increase of 3.78% [3] - The total number of ordinary shareholders at the end of the reporting period was 6,167 [3] - The top two shareholders, Wuxi Xiangsheng Investment Co., Ltd. and Mo Ruoli, hold 40.46% and 23.60% respectively, and are considered acting in concert [3]